THE US Food and Drug
Administration has approved
Synribo (omacetaxine
mepesuccinate) for the treatment
of adults with chronic myelogenous
leukaemia (CML) which is a blood
and bone marrow disease.
Synribo works by blocking
certaion proteins which promote
the development of cancerous
cells, and is injected
subcutaneously twice daily for 14
consecutive days over a four week
cycle until white blood cells
normalise in the patient.
A subsequent treatment round
involves twice daily injections for 7
days out of 28 as long as patients
continue to benefit from therapy.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Oct 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Oct 12
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.